Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
V. Trillet-Lenoir(Hôpital Louis Pradel), C. Ewen, Joachim von Pawel(Asklepios Fachkliniken München-Gauting), J. Green, A Depierre(National Cancer Centre Japan), Peter Johnson(Cancer Research UK), U. Gatzemeier(Ontario Institute for Cancer Research), Genevieve Decoster(Roche (Switzerland)), C. Manegold(Frauenklinik Heidelberg), Dianne Tomita, B Lebeau(Hôpital Saint-Antoine)
Cited by 545
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k